In summary, this study firstly demonstrates that dual targeting of RXR and HDAC using DW22 possesses pleiotropic antitumor activities in vitro and in vivo (Figure 7), providing a sound scientific base for developing this novel approach for treatment cancer. This evidence concerns the gene HDAC9 and cancer.